

HEALTH TECHNOLOGY BRIEFING JUNE 2019

VX-445/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation and one minimal function mutation in patients aged 12 years and older

| | | | |
|--------------------------|----------------------------|----------------|---------------|
| NIHRIO ID | 24207 | NICE ID | 10133 |
| Developer/Company | Vertex Pharmaceuticals Inc | UKPS ID | Not Available |

Licensing and market availability plans

The company plans to submit a Marketing Authorisation Application in Europe in Q4 2019 for VX-445 triple fixed-dose combination.^{1,2}

SUMMARY

The triple fixed-dose combination (FDC), VX-445/tezacaftor/ivacaftor-FDC, is in clinical development for cystic fibrosis (CF) that is heterozygous for F508del mutation and a minimal function mutation for patients aged 12 years and older. CF is the most common, life-limiting recessively inherited (a faulty gene inherited from both parents) disease in the UK. Genetic mutations affect the CF transmembrane conductance regulator (CFTR) gene, which is essential for the regulation of salt and water movements across cell membranes. These mutations mean that the CFTR protein is not processed and moved through the cells normally, resulting in little to no CFTR protein at the cell surface. This results in thickened secretions in organs with epithelial cell lining, mainly affecting the lungs and digestive system.

VX-445 and tezacaftor are designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the F508del CFTR protein. Ivacaftor is designed to enhance the function of the CFTR protein once it reaches the cell surface. The triple therapy of VX-445/tezacaftor/ivacaftor-FDC may result in an effective therapeutic option for people with CF with F508del mutations, who currently have limited options.

This briefing reflects the evidence available at the time of writing and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. The company was unavailable to comment.

PROPOSED INDICATION

Cystic fibrosis (CF) heterozygous for F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and a minimal function (MF) mutation (F/MF) - patients aged 12 years and older³

TECHNOLOGY

DESCRIPTION

The triple fixed-dose combination (FDC) of VX-445, tezacaftor and ivacaftor (VX-445/tezacaftor/ivacaftor-FDC) is in clinical development for patients aged 12 years and older who have CF that is heterozygous for F508del mutation in the CFTR gene and a minimal function mutation (F/MF).¹ Currently eligible minimal function mutations are outlined by the company.⁴

VX-445 is a next-generation CFTR corrector designed to restore F508del CFTR protein function in patients with CF when administered with tezacaftor and ivacaftor.⁵

Tezacaftor is a selective CFTR corrector that binds to the first Membrane Spanning Domain (MSD-1) of CFTR. Tezacaftor facilitates the cellular processing and trafficking of normal or multiple mutant forms of CFTR (including F508del-CFTR) to increase the amount of CFTR protein delivered to the cell surface, resulting in increased chloride transport in vitro.⁶

Ivacaftor is a CFTR potentiator that potentiates the channel-open probability (or gating) of CFTR at the cell surface to increase chloride transport. For ivacaftor to function CFTR protein must be present at the cell surface. Ivacaftor can potentiate the CFTR protein delivered to the cell surface by tezacaftor, leading to a further enhancement of chloride transport than either active substance alone. The combination targets the abnormal CFTR protein by increasing the quantity and function of CFTR at the cell surface and subsequently increasing airway surface liquid height, and ciliary beat frequency in vitro in human bronchial epithelial (HBE) cells from homozygous F508del CF patients. The exact mechanisms by which tezacaftor improves cellular processing and trafficking of F508del-CFTR and ivacaftor potentiates F508del-CFTR are not known.⁶

In the phase III clinical trial NCT03525444, patients were administered the triple FDC tablets of VX-445 200mg, tezacaftor 100mg and ivacaftor 150mg in the morning, followed by ivacaftor 150mg single tablet in the evening.³ There is also a phase III extension study NCT03525574, in which patients receive active treatment for up to 96 weeks.⁷

INNOVATION AND/OR ADVANTAGES

Whilst the dual combination of a first-generation CFTR corrector (lumacaftor or tezacaftor) and ivacaftor provides both short-term and long-term benefit to patients with F/F genotype, these combinations do not fully restore function to F508del CFTR protein and are not sufficiently active to improve outcomes in patients with F/MF genotypes.⁸

It has been shown in vitro that a combination of two correctors with distinct binding sites on CFTR and complementary mechanisms of action can increase the amount of F508del CFTR protein at the cell surface to a greater extent than either corrector alone.⁸

VX-445 shares some structural similarities and a mechanism of action with VX-659.⁵ VX-659 has been developed for use in combination with tezacaftor and ivacaftor to increase both the amount and function of F508del CFTR protein to a greater extent than a dual combination of a corrector and a potentiator. Additivity of VX-659 to tezacaftor and ivacaftor in vitro increases F508del CFTR protein processing within the cell and trafficking to the cell surface.⁸

Because VX-445 and VX-659 work through different mechanisms from tezacaftor, it is believed that the combination will increase the amount of F508del CFTR protein at the cell surface more than either compound alone, an effect that could be potentiated by ivacaftor to further increase chloride transport.^{5,8} The use of VX-445/tezacaftor/ivacaftor to target F508del CFTR protein has previously resulted in increased CFTR function in vitro and translated to improvements in patients with CF with one or two F508del alleles. This approach has the potential to treat the underlying cause of CF in approximately 90% of patients.⁵

DEVELOPMENT STATUS AND/OR REGULATORY DESIGNATIONS

VX-445/tezacaftor/ivacaftor-FDC does not currently have Marketing Authorisation in the EU/UK for any indication.

The treatment regimen of VX-445/tezacaftor/ivacaftor-FDC was granted orphan drug designation in the EU in December 2018 for the treatment of CF.⁹

The medicinal product tezacaftor/ivacaftor (tezacaftor 100mg/ ivacaftor 150mg) in a combination regimen with ivacaftor(150mg) has been granted Marketing Authorisation in the EU for patients aged 12 years and older with CF homozygous for F508del mutation or with CF heterozygous for F508del mutation and have one of another number of listed mutations.^{6,10} Very common adverse effects (>10%) in patients treated with tezacaftor/ivacaftor in combination with ivacaftor include nasopharyngitis and headache.⁶

The medicinal product tezacaftor/ivacaftor was designated an orphan drug in the EU in February 2017, and this designation was maintained at the time of Marketing Authorisation.¹¹

The medicinal product ivacaftor has been granted Marketing Authorisation in the EU for:¹²

- the treatment of patients with cystic fibrosis (CF) aged 6 years and older and weighing 25 kg or more who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R
- the treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an R117H mutation in the CFTR gene

The medicinal product ivacaftor was designated an orphan drug in the EU in July 2008, and this designation was maintained at the time of Marketing Authorisation.¹³

VX-445/tezacaftor/ivacaftor-FDC is also in phase III clinical development for patients aged 12 years and older with CF that is homozygous for F508del mutation, and for patients aged 6 to 11 years with CF with F/F or F/MF genotypes.^{14,15}

PATIENT GROUP

DISEASE BACKGROUND

CF results from mutations affecting a gene that encodes for the CFTR (a chloride channel) which is essential for the regulation of salt and water movements across cell membranes. Absent or reduced function of CFTR results in thickened secretions in organs with epithelial

cell lining, hence it is multi-system, although mainly affects the lungs, digestive system and vas deferens (part of the male reproductive system).¹⁶

In CF, the airways become clogged with thick sticky mucus, which impairs the clearance of microorganisms. This leads to recurrent infection, inflammation, bronchial damage, bronchiectasis and eventually death from respiratory failure. Patients are often infected with *S. aureus* and *P. aeruginosa*, but also by a number of other organisms, some of which are resistant to many antibiotics.¹⁶

In about 85% of cases the pancreatic exocrine ducts become sufficiently blocked to cause maldigestion and intestinal malabsorption (pancreatic insufficiency). Infants may fail to thrive, and older children and adults may become under-nourished. Appetite is often adversely affected which is a problem as there is an underlying increase in metabolic demands leading to a need for an increased energy intake. Other complications include male infertility, CF-related diabetes, chronic liver disease and portal hypertension, joints affected by CF-arthropathy, bones affected by reduced bone mineral density, and behavioural and psychological problems associated with a severe long-term medical condition.¹⁶

CLINICAL NEED AND BURDEN OF DISEASE

Cystic fibrosis (CF) is the most common, life-limiting recessively inherited disease in the UK.¹⁶ The latest annual report from the UK Cystic Fibrosis Registry shows that in 2017:¹⁷

- 10,469 people in the UK had a diagnosis of CF
- 214 patients were newly-diagnosed, of which 172 were identified by newborn screening
- 132 people with CF died, and the median age at death was 31 years
- 6,878 patients were aged 12 years and older (69.6% of patients who had annual reviews)
- 9,818 (99.3%) patients have been genotyped, of which 3,990 (40.4%) were heterozygous for F508del mutation

In England in 2017/18 there were 13,592 hospital admissions for all ages with a primary diagnosis of CF (ICD-10 code E84), resulting in 88,098 finished consultant episode (FCE) bed days.¹⁸

PATIENT TREATMENT PATHWAY

TREATMENT PATHWAY

Care for people with CF should be provided by a specialist CF multidisciplinary team (MDT) based at a specialist CF centre. The MDT should include specialist paediatricians or adult physicians, nurses, physiotherapists, dietitians, pharmacists and clinical psychologists. Patients should have a comprehensive annual review, and routine reviews at regular intervals.¹⁹

Current treatments for CF manage the symptoms and complications rather than the cause of the disease.²⁰

CURRENT TREATMENT OPTIONS

Treatments can be broadly classified as:²⁰

- nutritional repletion (for example, pancreatic enzymes and nutritional supplements)
- relief of airway obstruction (for example, physiotherapy, drugs to improve clearance of mucus such as dornase alfa [rhDNase], hypertonic saline, and bronchodilators)

- treatment of acute infections
- suppression of chronic infection
- suppression of inflammation (for example, steroids, high dose ibuprofen)
- lung transplantation

NICE recommends mannitol dry powder for inhalation as an option for treating CF in adults who cannot use rhDNase and whose lung function is rapidly declining and for whom other osmotic agents are not considered appropriate.²¹

PLACE OF TECHNOLOGY

If licensed, VX-445/tezacaftor/ivacaftor-FDC will offer a treatment option for patients aged 12 years and older with CF with F/MF genotype, who currently have no available CFTR modulator therapy.

CLINICAL TRIAL INFORMATION

| | | |
|------------------------------|---|--|
| Trial | NCT03525444 , EudraCT-2018-000183-28 , VX17-445-102; heterozygous for F508del mutation and a minimal function (MF) mutation (F/MF); VX-445/tezacaftor/ivacaftor vs tezacaftor/ivacaftor; phase III | NCT03525574 , EudraCT-2018-000185-11 , VX17-445-105; heterozygous or homozygous for F508del mutation (F/F); VX-445-tezacaftor-ivacaftor; phase III extension |
| Sponsor | Vertex Pharmaceuticals Inc | Vertex Pharmaceuticals Inc |
| Status | Completed | Ongoing |
| Source of Information | Trial registry, ³ press release ¹ | Trial registry ⁷ |
| Location | EU (incl UK), USA, Canada and Australia | EU (incl UK), USA, Canada and Australia |
| Design | Randomised, placebo controlled | Single group assignment, open label |
| Participants | n=405; aged 12 yrs and older; cystic fibrosis; heterozygous for F508del mutation and a minimal function (MF) mutation (F/MF); forced expiratory volume in 1 second (FEV1) value $\geq 40\%$ and $\leq 90\%$ of predicted mean for age, sex and height | Previously participated in parent studies NCT03525444 or NCT03525548 |
| Schedule | Randomised to fixed dose combination (FDC) of VX-445 200mg / tezacaftor 100mg / ivacaftor 150mg tablets in the morning, ivacaftor 150mg tablet in the evening, vs triple placebo | Fixed dose combination (FDC) of VX-445 200mg / tezacaftor 100mg / ivacaftor 150mg tablets in the morning, ivacaftor 150mg tablet in the evening |
| Follow-up | Active treatment for 24 wks, safety follow-up for 4 wks | Active treatment up to 96 wks, safety follow-up for 4 wks (up to 100 wks) |

| | | |
|---------------------------|---|--|
| Primary Outcomes | Absolute change in percent predicted FEV1 (ppFEV1) [Time frame: from baseline at wk 4]. | Safety and tolerability based on adverse events (AEs) and serious adverse events (SAEs) [Time frame: from baseline through safety follow-up (up to 100 wks)] |
| Secondary Outcomes | <ul style="list-style-type: none"> • Absolute change in ppFEV1 [Time frame: from baseline through wk 24] • Number of pulmonary exacerbations (PEX) [Time frame: from baseline through wk 24] • Time to first PEX [Time frame: through wk 24] • Absolute change in body mass index (BMI) [Time frame: from baseline at wk 24] • Absolute change in BMI z-score [Time frame: from baseline at wk 24] • Absolute change in body weight [Time frame: from baseline at wk 24] • Absolute change in sweat chloride [Time frame: from baseline at wk 4 and through wk 24] • Absolute change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score [Time frame: from baseline at wk 4 and through wk 24] • Safety and tolerability assessed by number of subjects with AEs and serious adverse events (SAEs) [Time frame: from baseline through 4-wk safety follow-up (up to 28 wks)] • Observed pre-dose concentration (Ctrough) of VX-445, tezacaftor, metabolite M1-tezacaftor, and ivacaftor [Time frame: from day 1 through wk 16] | <p>Time frame: from baseline through last dose of study drug (up to 96 wks):</p> <ul style="list-style-type: none"> • Absolute change from baseline in ppFEV1 • Absolute change in sweat chloride • Number of pulmonary exacerbations (PEX) • Time to first PEX • Absolute change in body mass index (BMI) • Absolute change in BMI z-score • Absolute change in body weight • Absolute change from baseline in CFQ-R respiratory domain score |
| Key Results | <p>Mean absolute improvement in ppFEV1 of 13.8 % points from baseline at wk 4 in VX-445-tezacaftor-ivacaftor group compared to triple placebo group ($p < 0.0001$).</p> <p>Mean absolute within-group improvement in ppFEV1 from baseline for VX-445-tezacaftor-</p> | - |

| | | |
|--------------------------------|---|--|
| | ivacaftor group was 13.6 % points from baseline at wk 4. Mean absolute within-group change in ppFEV1 from baseline for triple placebo group was -0.2 % points from baseline at wk 4. | |
| Adverse effects (AEs) | VX-445/tezacaftor/ivacaftor-FDC regimen generally well tolerated. | - |
| Expected reporting date | Study completion date reported as April 2019. | Study completion date reported as June 2021. |

| | | |
|------------------------------|---|--|
| Trial | NCT03227471 , EudraCT-2017-000797-11 , VX16-445-001; heterozygous for F508del mutation and a minimal function (MF) mutation (F/MF) or homozygous for F508del mutation (F/F); VX-445-tezacaftor-ivacaftor vs placebo; phase I/II | |
| Sponsor | Vertex Pharmaceuticals Inc | |
| Status | Published | |
| Source of Information | Publication ^{5,22} , trial registry ²³ | |
| Location | EU (excl UK), USA and Australia | |
| Design | Randomised, placebo-controlled | |
| Participants | n=123 (95 with F/MF genotype, 28 with F/F genotype); aged 18 yrs and older; cystic fibrosis; heterozygous for F508del mutation and a MF mutation (F/MF), or homozygous for F508del mutation (F/F); FEV1 value ≥40% and ≤90% of predicted mean for age, sex and height | |
| Schedule | Pts with F/F genotype: <ul style="list-style-type: none"> • Run-in: tezacaftor/ivacaftor tablets in the morning, ivacaftor tablet in the evening • Pts then randomised to FDC of VX-445 200mg/tezacaftor 100mg/ivacaftor 150mg tablets in the morning, ivacaftor 150mg tablet in the evening, or matched placebo plus tezacaftor and ivacaftor | |
| Follow-up | 4-wk run-in prior to randomisation, active treatment for 4 wks, safety follow-up for 5 wks | |
| Primary Outcomes | <ul style="list-style-type: none"> • Safety and tolerability assessed by number of subjects with AEs and SAEs [Time frame: from baseline through safety follow-up (up to 35 days after last dose)] • Absolute change in ppFEV1 [Time frame: from baseline through day 29] | |
| Secondary Outcomes | Time frame: from baseline through day 29: <ul style="list-style-type: none"> • Absolute change in sweat chloride concentrations • Relative change in ppFEV1 • Absolute change in CFQ-R respiratory domain score Time frame: from day 1 through day 43: <ul style="list-style-type: none"> • Maximum observed concentration (C_{max}) of VX-445, tezacaftor and metabolites (M1-tezacaftor and M2-tezacaftor), ivacaftor and metabolites (M1-ivacaftor and M6-ivacaftor) and VX-561 • Area under the concentration versus time curve during a dosing interval (AUC_{tau}) of VX-445, tezacaftor and metabolites (M1- | |

| | |
|------------------------------|--|
| | <p>tezacaftor and M2-tezacaftor), ivacaftor and metabolites (M1-ivacaftor and M6-ivacaftor) and VX-561</p> <ul style="list-style-type: none"> Observed pre-dose concentration (C_{trough}) of VX-445, tezacaftor and metabolites (M1-tezacaftor and M2-tezacaftor), ivacaftor and metabolites (M1-ivacaftor and M6-ivacaftor) and VX-561 |
| Key Results | <p>Treatment with VX-445/tezacaftor/ivacaftor resulted in significant improvements over baseline in ppFEV₁, by up to 13.8 % points in pts with F/MF genotype, and up to 11.0 % points in pts with F/F genotype. Improvements in ppFEV₁ were observed at the first assessment on day 15 and maintained at day 29. Improvements were also seen for both genotype groups for sweat chloride concentration (indicating improved CFTR function) and CFQ-R respiratory domain score.</p> |
| Adverse effects (AEs) | <p>VX-445/tezacaftor/ivacaftor FDC regimen had an acceptable AE profile in both F/F and F/MF genotypes. 68 or 74 pts who received VX-445/tezacaftor/ivacaftor (92%) reported at least 1 AE, as did 12 pts who received triple placebo (100%) and 5 of 7 pts who received tezacaftor-ivacaftor (71%). Among the 68 pts who received VX-445/tezacaftor/ivacaftor and had an AE, 36 (53%) had mild events, 29 (43%) had moderate events, and 3 (4%) had severe events. SAEs occurred in 3 pts (4%) in the VX-445-tezacaftor-ivacaftor group, 2 pts (17%) in the triple placebo group, and 1 pt (14%) in the tezacaftor-ivacaftor group. Five SAEs occurred in 3 pts receiving VX-445/tezacaftor/ivacaftor with 2 events of infective pulmonary exacerbations of CF and 2 events of distal intestinal obstruction syndrome; 1 pt who had both distal intestinal obstruction syndrome and infective pulmonary exacerbation of CF also had a SAE of jugular venous thrombosis.</p> <p>3 pts in the VX-445/tezacaftor/ivacaftor group and 1 pt in the control group discontinued treatment because of AE.</p> <p>The most common AEs (>10%) in pts taking VX-445/tezacaftor/ivacaftor were cough, increased sputum production, infective pulmonary exacerbation of CF, hemoptysis, and pyrexia. The incidence of abnormal results on tests of liver function (>3 times the upper limit of the normal range for levels of aspartate aminotransferase or alanine aminotransferase, was 8%. The incidence of elevation of bilirubin levels >2 times the upper limit of normal was 3%.</p> |

ESTIMATED COST

The cost of the treatment regimen of VX-445/tezacaftor/ivacaftor-FDC is not yet known.

RELEVANT GUIDANCE

NICE GUIDANCE

- NICE technology appraisal. Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398). July 2016.
- NICE technology appraisal. Mannitol dry powder for inhalation for treating cystic fibrosis (TA266). November 2012.
- NICE guideline. Cystic fibrosis: diagnosis and management (NG78). October 2017.

- NICE quality standard. Cystic fibrosis (QS168). May 2018.

NHS ENGLAND (POLICY/COMMISSIONING) GUIDANCE

- NHS England. Service Specification: Cystic fibrosis (adults). A01/S/a.
- NHS England. Service Specification: Cystic fibrosis (children). A01/S/b.

OTHER GUIDANCE

- Cystic Fibrosis Trust. Standards for the clinical care of children and adults with cystic fibrosis in the UK. Second ed. December 2011.¹⁶

ADDITIONAL INFORMATION

Vertex did not enter information about this technology onto the UK PharmaScan database; the primary source of information for UK horizon scanning organisations on new medicines in development. As a result, the NIHR Innovation Observatory has had to obtain data from other sources. UK PharmaScan is an essential tool to support effective NHS forward planning; allowing more effective decision making and faster uptake of innovative new medicines for patients who could benefit. We urge pharmaceutical companies to use UK PharmaScan so that we can be assured of up-to-date, accurate and comprehensive information on new medicines.

REFERENCES

- 1 Vertex Pharmaceuticals Inc. *Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis*. 6 March 2019. Available from: <https://investors.vrtx.com/news-releases/news-release-details/correcting-and-replacing-two-phase-3-studies-triple-combination> [Accessed 25 March 2019].
- 2 Reuters. *Vertex to file for approval of cystic fibrosis therapy in 2019*. Available from: <https://uk.reuters.com/article/vertex-pharms-fda/vertex-to-file-for-approval-of-cystic-fibrosis-therapy-in-2019-idUKL4N2363DM> [Accessed 24 June 2019].
- 3 ClinicalTrials.gov. *A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)*. Trial ID: NCT03525444. Status: Active, not recruiting. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT03525444> [Accessed 8 April 2019].
- 4 Vertex Pharmaceuticals Inc. *CFTR Mutations Eligible for Phase 3 Studies of Investigational VX-659 or VX-445 Triple Combination Regimens in People with One F508del Mutation and One Minimal Function Mutation*. Available from: <https://www.vrtx.com/sites/default/files/VX659VX445Ph3MFmutations.pdf> [Accessed 18 March 2019].
- 5 Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, et al. VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. *The New England Journal of Medicine*. 2018;379(17):1612-20. Available from: 10.1056/NEJMoa1807120.
- 6 Electronic Medicines Compendium. *Symkevi 100 mg/150 mg film coated tablets*. Available from: <https://www.medicines.org.uk/emc/product/9634/smpc> [Accessed 27 February 2019].
- 7 ClinicalTrials.gov. *A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy*. Trial ID: NCT03525574. Status: Enrolling by invitation. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT03525574> [Accessed 5 April 2019].

- 8 Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, et al. VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. *New England Journal of Medicine*. 2018;379(17):1599-611. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa1807119>.
- 9 European Medicines Agency (EMA). *Public summary of opinion on orphan designation: Ivacaftor, N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[[4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, tezacaftor for the treatment of cystic fibrosis*. Committee for Orphan Medicinal Products; 2019. Report No.: EMA/828204/2018. Available from: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/18/2116-public-summary-opinion-orphan-designation-ivacaftor-n-13-dimethyl-1h-pyrazole-4-sulfonyl-6-3_en.pdf.
- 10 European Commission. *Union Register of medicinal products for human use*. Available from: <http://ec.europa.eu/health/documents/community-register/html/h1306.htm> [Accessed 27 February 2019].
- 11 European Medicines Agency (EMA). EU/3/17/1828. Available from: <https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171828> [Accessed 20 March 2019].
- 12 Electronic Medicines Compendium. *Kalydeco 150 mg film-coated tablets*. Available from: <https://www.medicines.org.uk/emc/product/3040/smpc> [Accessed 20 March 2019].
- 13 European Medicines Agency (EMA). EU/3/08/556. Available from: <https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu308556> [Accessed 20 March 2019].
- 14 ClinicalTrials.gov. *A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)*. Trial ID: NCT03525548. Status: Completed. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT03525548> [Accessed 5 April 2019].
- 15 ClinicalTrials.gov. *Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age*. Trial ID: NCT03691779. Status: Recruiting. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT03691779> [Accessed 25 March 2019].
- 16 Cystic Fibrosis Trust. *Standards for the clinical care of children and adults with cystic fibrosis in the UK*. 2011. Available from: https://www.cysticfibrosis.org.uk/~/_media/documents/the-work-we-do/care/consensus-docs-with-new-address/cystic-fibrosis-trust-standards-of-care.ashx?la=en.
- 17 UK Cystic Fibrosis Registry. *Cystic Fibrosis: Strength in Numbers. Annual Data Report 2017*. August 2018. Available from: https://www.cysticfibrosis.org.uk/~/_media/documents/the-work-we-do/uk-cf-registry/2017-registry-annual-data-report-interactive.ashx?la=en.
- 18 NHS Digital. *Hospital Admitted Patient Care Activity, 2017-18: Diagnosis*. Available from: <https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/2017-18> [Downloaded 27 November 2018].
- 19 National Institute for Health and Care Excellence. *Cystic fibrosis: diagnosis and management (NG78)*. Last Update Date: October 2017. Available from: <https://www.nice.org.uk/guidance/ng78> [Accessed 27 February 2019].
- 20 National Institute for Health and Care Excellence. *Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation. Final scope*. May 2018. Available from: <https://www.nice.org.uk/guidance/gid-ta10277/documents/final-scope>.
- 21 National Institute for Health and Care Excellence. *Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)*. Last Update Date: November 2012. Available from: <https://www.nice.org.uk/guidance/ta266> [Accessed 27 February 2019].
- 22 VERTEX PHARMACEUTICALS INCORPORATED. *Clinical Study Protocol: A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation, and Food Effect Study Evaluating the Safety and Pharmacokinetics of VX-445 in Healthy Subjects* Available from:

https://www.nejm.org/doi/suppl/10.1056/NEJMoa1807120/suppl_file/nejmoa1807120_protocol.pdf [Accessed 26 June 2019].

- 23 ClinicalTrials.gov. *A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis*. Trial ID: NCT03227471. Status: Completed. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT03227471> [Accessed 5 April 2019].

NB: This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health.